Data / Drug companies / Plasma Kallikrein Inhibitor
Plasma Kallikrein Inhibitor drugs: 4 drugs from 3 companies in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Plasma Kallikrein Inhibitor is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 11 products in this class from 3 companies, covering 4 drugs by generic name. The main marketing category is new drug applications (NDA), and the newest product started marketing on October 15, 2026.
The request: Get every company that lists a Plasma Kallikrein Inhibitor drug in the FDA NDC directory, with headquarters, website and size. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 3Companies
- 11Products
- 4Drugs by generic name
Drugs in the Plasma Kallikrein Inhibitor class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Berotralstat hydrochloride | 7 | 1 |
| Lanadelumab-flyo | 2 | 1 |
| Ecallantide | 1 | 1 |
| Sebetralstat | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| BioCryst Pharmaceuticals Inc. | 7 | pellet; capsule | New drug applications (NDA) | October 15, 2026 |
| Takeda Pharmaceuticals America, Inc. | 3 | solution; injection, solution | Biologics (BLA) | February 3, 2023 |
| KalVista Pharmaceuticals Ltd | 1 | tablet | New drug applications (NDA) | July 3, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Pellet | 5 | 45.5% |
| Capsule | 2 | 18.2% |
| Solution | 2 | 18.2% |
| Injection, solution | 1 | 9.1% |
| Tablet | 1 | 9.1% |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.